Objectives: Sleep disturbance is a common comorbidity of chronic pain. Inflammatory processes are dysregulated in sleep disturbance and also contribute to pain sensitivity. Thus, inflammation may play an important role in bidirectional associations between pain and sleep. Little is known about concurrent relationships among chronic pain, sleep, and inflammation. The aim of our study was to examine associations between sleep disturbance and circulating levels of the inflammatory cytokine, interleukin-6 (IL-6), in individuals with and without chronic low back pain.
T he association between pain and sleep disturbance is bidirectional: pain contributes to disrupted sleep, and sleep disturbance can similarly enhance pain perception. [1] [2] [3] [4] [5] The neurobiologic mechanisms linking pain and sleep remain unclear. Recent attention to interactions between inflammatory processes in pain, on the one hand, and sleep, on the other, points to neuroimmunologic pathways that may contribute to the strong association between pain and sleep.
Proinflammatory cytokines, including interleukin-6 (IL-6), may be involved in pain processes. [6] [7] [8] Inflammatory mediators can modulate nociception 9 and contribute to the amplification and persistence of pain. [10] [11] [12] [13] In clinical studies, higher levels of IL-6 have been associated with greater pain severity in individuals with rheumatoid arthritis 14 and fibromyalgia 15 and with greater postoperative pain. 16 Although the nature of the relationship between IL-6 and pain is not fully understood, sleep disruption may be an important contributor to proinflammatory activity in those with chronic and recurrent pain. For example, IL-6 normally peaks approximately 2.5 hours after sleep onset and typically shows higher circulating levels at night. [17] [18] [19] [20] However, reductions in sleep quality and quantity have each been associated with higher circulating levels of IL-6 during the day. [20] [21] [22] [23] [24] To the authors' knowledge, only 1 study to date has simultaneously examined sleep, IL-6, and pain. Haack et al 23 randomly assigned 18 young women without sleep disorders to either a 50% reduction in usual sleep time (ie, 4 h per night) or an 8-hour sleep condition. Over a period of 10 days the women in the sleep reduction condition showed increased IL-6 levels and greater daily pain ratings compared with women sleeping 8 hours per night. 23 Although this study provides suggestive evidence for an association between sleep restriction, IL-6, and pain reports, it is difficult to generalize these findings to the potential relationship between naturally occurring sleep disturbance and clinical pain.
In this study, we assessed self-reported sleep quality and circulating IL-6 levels in a community-based sample of adults with and without chronic low back pain (CLBP). Intervertebral discs from CLBP patients have been shown to produce high levels of proinflammatory cytokines, including IL-6, 25 suggesting inflammatory contributions to back pain. Whether IL-6 levels in circulation are associated with sleep quality in adults with CLBP, however, is unknown. As the clinical observations indicate that inflammatory back pain tends to be greatest in the morning, in this study our focus was on morning pain after awakening. We predicted that individuals with CLBP would report poorer sleep quality, evidence more clinical sleep disturbance, have higher IL-6 levels, and will show stronger associations between IL-6 and sleep quality compared with healthy controls. We also expected that poorer sleep quality and IL-6 levels would be associated with more morning pain in CLBP. Finally, given the interrelationships among depression, pain, and sleep disturbance, 3, 5, 26 we also examined the potential influence of depressive symptoms on associations among pain, sleep, and IL-6.
MATERIALS AND METHODS

Participants
Twenty-five men and women with CLBP (defined as low back pain for 6 mo or more) were recruited, along with 25 age-matched and sex-matched individuals without chronic pain. The participants were recruited primarily through newspaper and posted advertisements; we also invited participants who had completed another study of CLBP 27 to participate in this study. Eligibility criteria paralleled the Trost et al 27 study and were as follows: no history of spinal surgeries; no orthopedic injuries to the upper or lower extremities that restrict motions of these segments; no lower extremity weakness or neurologic signs that reflect brain or nerve injury (eg, seizures, cerebral palsy); no prescription opioids for symptom relief; no chronic diseases that may restrict movement (eg, severe arthritis). Additional eligibility criteria included no current infectious, autoimmune or inflammatory diseases, or other diseases with obvious immunologic consequences (eg, rheumatoid arthritis, cardiovascular disease, cancer within the past 5 y); no diabetes or thyroid conditions; no heavy smoking (ie, >15 cigarettes daily); no reported needle or blood phobias; no current use of psychotropic medication (eg, antidepressants); no fibromyalgia.
Procedure
Eligible participants were enrolled in a 2-part study. The participants completed informed consent, a series of self-report questionnaires, and provided a blood sample at a morning study session (time 1); all blood samples were obtained by a research nurse between 8:30 am and 10:30 am. The participants were asked to refrain from alcohol and the use of antiinflammatory medications (eg, ibuprofen) for 24 hours before their blood draw. At home the next morning, the participants completed questionnaires regarding sleep during the previous night and their current morning pain (time 2). The participants received $20 for participation. All recruitment and study procedures were reviewed, approved, and monitored by the appropriate institutional review boards.
Key Measures
Pittsburgh Sleep Quality Index (PSQI): The PSQI is a 24-item scale that measures sleep disturbances along 7 dimensions, including subjective sleep quality, sleep latency (time it takes to fall asleep), sleep duration (time asleep while in bed), sleep efficiency (percentage of time asleep while in bed), sleep disturbance (eg, trouble sleeping because of bad dreams, need to use bathroom, coughing or snoring, pain), use of sleep medication, and daytime dysfunction. Scores from these 7 dimensions (ranging from 0 to 3) are individually reported as component scores and summed to derive a global sleep quality score (0 to 21). 28 In an earlier reliability and validity study, a cutoff of more than 6 resulted in best sensitivity and specificity with respect to insomnia, 29 a convention that we adopt in this study. At time 1, participants completed the PSQI with regard to sleep in the past month; at time 2 (the next morning after awakening), the participants completed a single-night PSQI with regard to sleep during the previous night only. We derived component and global scores from PSQI assessment at time 1 (reflecting sleep quality in the past month) and time 2 (single-night PSQI, reflecting sleep quality the previous night). The participants were categorized as having or not having clinical sleep disturbance (ie, a PSQI global score >6 and r6, respectively) from the PSQI assessment at time 1. We also report 2 single items from the scale that are useful self-report measures of sleep continuity disturbance observed in insomnia samples: total sleep duration (in hours) and sleep efficiency, which is the ratio of time spent in bed to total sleep duration (expressed as a percentage).
The single-night PSQI completed at time 2 differed from the original PSQI in 2 ways. First, 2 items assessing daytime dysfunction in the past month were modified to assess the expectations of daytime fatigue. Second, response options for these 2 items and for 9 items assessing types of sleep disturbances were modified from 0 (not during the past month) to 3 (3 or more times per week) scales to Yes or No, equaling 3 or 0, respectively. The original and singlenight PSQI global scores were significantly correlated (r=0.54, P=0.01).
McGill Pain Questionnaire-Short Form (MPQ-SF): We used the MPQ-SF, a commonly used, well-validated, reliable instrument for the assessment of current pain for clinical and research applications. 30 The respondents report their current pain intensity using a single-item rating of 6 pain levels, ranging from "no pain" to "excruciating." The respondents also rate 15 pain descriptors, including sensory (11 items, eg, throbbing, shooting) and affective (4 items, eg, sickening, fearful) descriptors, on a scale from 0 (none) to 3 (severe). Summation of descriptors provides both sensory and affective rating scores and a total pain rating score.
IL-6 levels: After venipuncture, the blood was kept on ice and centrifuged, and the plasma was stored at À801C. Plasma IL-6 concentrations were determined by an assay using standard ELISA protocols and high-sensitivity anticytokine antibody pairs (R&D Systems, Minneapolis, MN). Absorbance was measured at 405/630 nm using an automated Opsys MR Microplate Reader (Thermo Labsystems, Chantilly, VA). Sensitivity for the assay was 0.039 pg/mL and intraassay and interassay variation was <10%.
Potential Covariates
Demographics and health questionnaire: We assessed demographics (race/ethnicity, relationship status), smoking (frequency, amount of tobacco use), exercise (frequency, amount of moderate-to-highly vigorous physical activity for 30 min or more), caffeinated beverage consumption, hypertension and other chronic conditions, current medications, and verified inclusion criteria using a form developed for this study.
Center for Epidemiological Studies Depression Scale-Revised (CESD-R): The CESD-R is a well-validated 20-item measure of depressive symptoms in the previous week. 31 In many populations, large proportions of individuals with CESD scores greater than 15 meet diagnostic criteria for major depression. 32 Responses involve a 4-point Likert scale ranging from 0 ("not at all") to 3 ("nearly every day"). For descriptive purposes we report total CESD-R scores. For analyses, we use the total score with the sleep items removed, as has been recommended. 33 
Data Analysis
Characteristics of individuals with CLBP and without chronic pain (controls) were compared using w 2 tests (categorical variables) or independent t tests (continuous variables). The following served as the dependent variables for key group comparisons: global PSQI scores at time 1 (past month) and time 2 (previous night), presence of sleep disturbance (PSQI>6), and log-transformed IL-6 levels. PSQI component scores (used to derive global PSQI score) and sleep efficiency and total sleep time scores were also examined. Pearson correlation coefficients were evaluated to determine associations between IL-6 levels and global PSQI scores at time 1 and time 2 for participants with and without CLBP. In the CLBP group, we also examined correlations between MPQ-SF pain scores, and PSQI scores and IL-6. Age-modified and CESD-R-modified scores (ie, excluding sleep items) were examined as potential covariates given their associations with IL-6 levels 34, 35 and sleep. 22 
RESULTS
Characteristics of Individuals With and Without CLBP
The participants were primarily female (60%), White, non-Hispanic (92%), young adults (age: M=30.8 y; SD= 11.4; range=19 to 55 y), and approximately half were in a romantic relationship (57%); there were no differences in these variables between individuals with and without CLBP (Ps>0.8). Average caffeine use (M=2.3 cups daily; SD=2.1) and the number of individuals who engaged in regular exercise (64%), were smokers (12%), or had consumed caffeine before the blood draw (30%), were also similar for individuals with and without CLBP (all Ps>0.50). Two women with CLBP and 1 woman without chronic pain were postmenopausal. One CLBP participant reported hypertension and the use of a diuretic and an angiotensin-converting enzyme (ACE) inhibitor. No participants reported statin use. One man with CLBP reported taking an antiinflammatory medication (hydrocortisone tablet) 25 hours before his blood draw; however, excluding him from analyses did not alter results reported here.
Key Comparisons: Sleep and IL-6 Levels by Group
Descriptive statistics for PSQI measures are presented in Table 1 . At time 1, participants with CLBP had higher global PSQI scores compared with controls, indicating poorer sleep quality in the past month. CLBP participants also had a larger proportion of individuals with a global PSQI score greater than 6 [n=13 (52%) compared with controls, n=5 (20%); w 2 =5.56, P=0.04], indicating more clinically meaningful sleep disturbance among adults with CLBP. On the basis of PSQI component scores, individuals with CLBP reported more sleep disturbances, greater daytime dysfunction, and marginally lower habitual sleep efficiency compared with controls. No group differences were evident for total sleep time. At time 2, singlenight PSQI global scores (reflecting sleep the previous night) were higher for the CLBP group (Table 1) . Outcomes for the single-night PSQI component scores were similar overall to those for the past month PSQI, but sleep efficiency was also lower in the CLBP group compared with controls. Finally, circulating IL-6 levels did not differ between participants with CLBP (M=1.2 pg/mL; SD=1.0) versus controls (M=1.1 pg/mL, SD=0.6; t(48)=0.44; P=0.67).
Age was not associated with sleep measures at either time point. When groups were combined, the correlation between age and IL-6 levels was not significant (r=0.24, P=0.10); when we stratified by group, the controls evidenced a moderate correlation between age and IL-6 (r=0.34, P=0.09), whereas adults with CLBP did not (r=0.15, P=0.48).
Associations Between IL-6 and Sleep Quality
In the CLBP group, lower sleep quality was associated with higher IL-6 levels (time 1 PSQI: r=0.39, P=0.05; time 2 PSQI: r=0.52, P=0.008). Among the controls, IL-6 levels were not associated with PSQI scores (time 1 PSQI: r=0.22, P=0.29; time 2 PSQI: r=0.18, P=0.39). IL-6 levels by PSQI global scores are plotted for all participants in Figure 1A (Time 1) and 1B (Time 2). Overall, individuals characterized as poor sleepers (global PSQI score >6; n=18/50, or 36% of participants), a majority of whom were participants with CLBP (n=13/18, or 72.2%), had higher IL-6 levels compared with good sleepers (poor sleepers, M=1.40 pg/mL, SD=1.01; good sleepers, M= 0.99 pg/mL, SD=0.70; F (1, 49)=4.61, P=0.04). 
Associations Among Sleep Quality, IL-6 Levels, and Pain Ratings in Adults With CLBP
In the CLBP group, PSQI global sleep quality (past month) was strongly associated with MPQ-SF assessments of morning pain, including higher MPQ-SF total scores (r=0.51, P=0.01), and higher sensory (r=0.43, P=0.03) and affective pain ratings (r=0.56, P=0.004). Single-night PSQI scores were also associated with MPQ-SF affective scores (r=0.47, P=0.02), but not with total or sensory scores. Higher IL-6 levels were also associated with higher MPQ-SF affective pain ratings (r=0.46, P=0.02).
We explored whether controlling for sleep quality scores would mitigate (and therefore potentially mediate) associations between affective pain ratings and IL-6. When regressing affective pain ratings onto PSQI scores and IL-6, global sleep quality remained a significant predictor of affective pain (B=0.16; P=0.02), whereas IL-6 levels were no longer significantly related to pain (B=1.06; P=0.14).
Do Depressive Symptoms Explain Associations Among Sleep Disturbance, IL-6, and Pain?
CESD-R scores (minus sleep items) were significantly higher among those with CLBP (M=17.0; SD=12.7) compared with those without chronic pain (M=6.9; SD=5.3), after adjusting the degrees of freedom for unequal variances [t(32.1)= À3.63, P=0.001]. Among the CLBP group, R coefficients indicated moderate, although nonstatistically significant, associations between CESD-R-modified scores and sleep (PSQI past month: r=0.37, P=0.07; single-night PSQI: r=0.24, P=0.25), IL-6 (r=0.31. P=0.13), and pain (MPQ-SF total: r=0.35, P=0.08), particularly affective pain ratings (affective: r=0.39, P=0.05; sensory: r=0.30, P=0.15). Thus, we next conducted separate analyses regressing sleep onto IL-6 and sleep onto pain ratings while controlling for CESD-R-modified scores to evaluate whether depressed mood was a potential mediator of sleep and IL-6, and pain relationships.
In contrast, controlling for depressive symptoms did not weaken the association between single-night PSQI global score and IL-6 level (B=0.48, P=0.02), but did render the association between the past month PSQI global score and IL-6 level nonsignificant (B=0. 31, P=0.14) . Notably, the associations between sleep quality (past month and previous night) and pain ratings were unchanged after controlling for depressive symptoms.
DISCUSSION
Our findings support a role for sleep disturbance and associated inflammatory processes in understanding bidirectional associations among pain and sleep. In adults with CLBP, we found poorer subjective sleep quality to be associated with higher levels of the inflammatory cytokine, IL-6. This association is especially noteworthy given the absence in our sample of common chronic back pain comorbidities, such as heart disease, rheumatoid arthritis, or diabetes, 36 which are characterized by inflammatory dysregulation and elevated IL-6. 35, 37 Thus, we suspect that our findings may underestimate the bidirectional associations among sleep, IL-6, and pain, which may be particularly problematic for individuals with chronic pain comorbidities and an associated inflammatory burden. Our evidence also suggests that sleep and IL-6 play a role in pain perceptions. Poorer sleep quality was associated with higher morning pain. IL-6 levels were related only to affective pain ratings, and this association was mediated by sleep quality. To explore this relationship further, we examined associations between IL-6 and specific affective pain descriptors from the MPQ-SF. We found that higher IL-6 levels were strongly associated with higher ratings of current pain being "tiring/exhausting" (r=0.58, P=0.002), a relationship that was not attenuated by including sleep quality in the model. This finding suggests that individuals may attribute daytime fatigue to pain, rather than to its more likely source: sleep disturbance and concomitant increases in IL-6 levels. Inflammatory cytokines have multiple effects on the central nervous system, producing "sickness behaviors" that include both hyperalgesia and fatigue. 26, 38 Misattribution of negative affect and fatigue to pain may lead to greater fear-avoidant behavior and disability, 39 a prospect that remains to be tested.
As expected, depressive symptom scores were significantly higher among our CLBP group compared with controls. 40 However, depression did not fully explain associations between IL-6 and sleep, and poor sleep quality remained a significant predictor of pain after adjusting for depressive symptoms. Given the strong associations between depression and insomnia, and depression and pain, depressed mood likely plays an important role in the neurobiologic pathways linking pain and sleep. Nevertheless, it is also probable that depression is neither necessary nor sufficient for persistent pain to be underpinned by sleep and inflammatory processes. In addition, sickness behaviors, all of which can characterize clinical depression, 41, 42 may be a consequence of pain and sleep-related inflammatory function. Longitudinal studies evaluating pain, sleep, mood, and inflammation are necessary to fully delineate the nature of these complex and bidirectional associations.
Our findings in the context of emerging literature on inflammation and pain, and sleep, suggest that the mechanisms underpinning increased IL-6 among chronic pain sufferers with sleep disturbance warrant scrutiny. Recent psychoneuroimmunologic research suggests a role for inflammatory mediators in hyperalgesia, including exacerbated back pain, 7,11 possibly through direct effects of inflammatory cytokines on pain sensory pathways. 10, 12, [43] [44] [45] These links, however, are not fully understood. Sleep disturbance, as a modulator of inflammation, may contribute to this process. Stress pathways may be involved as well. 46 Notably, nociceptive stimulation can lead to inflammatory reactivity, 47, 48 and, in a recent study, IL-6 responses were attenuated in individuals reporting less pain-related catastrophizing. 49 Thus, pain-associated stress and anxiety may exacerbate pain through heightened inflammatory responses to nociception. Sleep disturbance, too, can modulate physiological stress reactivity. 50, 51 Future research should assess both sleep disturbance and pain-related stress reactivity as a source of increased systemic inflammation in pain disorders.
Limitations of this study include a small sample size and the inclusion of otherwise healthy and relatively young adults with CLBP. Despite the small sample, we found significant associations among poorer sleep quality and higher IL-6. Further, inflammatory dysregulation increases with age and higher IL-6 levels are associated with agerelated sleep changes. 22 Thus, the association we observed here between sleep disturbance and inflammation in younger to middle-aged adults with chronic pain may be particularly problematic for older adults with chronic pain. Controls showed the expected age-related increases in IL-6, 34, 35 although age and IL-6 correlation was nonsignificant (P=0.09). In contrast, for the CLBP group, age showed no association with IL-6 (P=0.48). The most parsimonious explanation is that there is no significant association within either group, which may be because of our smaller and younger sample. Alternatively, variation in sleep quality may play a more prominent role in the inflammatory function among individuals with chronic pain than does chronological age.
Additional limitations include the use of a modified version of the PSQI to assess sleep quality during a single night, which has yet to be fully validated, and a single blood sample. Multiple assessments of IL-6 throughout the day on multiple days would allow for an analysis of change and improved reliability. Whether venipuncture pain affected outcomes is also unknown. We did not have information on factors such as body mass index, estradiol levels, or 12-hour preblood draw diet (as this was not a fasting blood draw), any of which may have been related to sleep, 52,53 IL-6, [54] [55] [56] or pain 57, 58 in our sample. Whether these factors can explain our findings warrants future study. Nonetheless, our exclusion criteria do reduce the likelihood that relationships observed here are because of confounding by inflammatory-related conditions. Finally, we assessed fibromyalgia and inflammatory conditions characterized by episodic pain (eg, rheumatoid arthritis), but we did not specifically inquire about all episodic pain conditions (eg, migraine, mennorhagia). Thus, we cannot rule out the possibility that these conditions were present and influenced our findings.
In sum, these findings suggest important roles for sleep disturbance and associated inflammatory processes in chronic pain, which require further study. Notably, we have also found that improving sleep in adults with insomnia as a secondary comorbidity to chronic pain leads to reductions in circulating IL-6. 59 Adults with noncancer, nonsite-specific chronic pain and insomnia, who received cognitive-behavioral treatment (CBT) that included a sleep intervention component had significantly larger declines in IL-6 levels after treatment compared with a group receiving CBT without attention to sleep. These encouraging data underscore significant clinical implications of understanding pathways linking sleep, inflammation, and pain, and support explicit treatment of sleep problems in the management of chronic pain. Given the strong associations we observed between sleep and IL-6 in our study, these implications may indeed be similar in the context of CLBP.
